ArticleCureus2026
Addition of Clomiphene Citrate to a Low-Dose Gonadotropin-Releasing Hormone (GnRH)-Antagonist Protocol in Poor Responders: A Prospective Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate whether the addition of clomiphene citrate (CC) to a low-dose recombinant follicle-stimulating hormone (FSH) (r-FSH) gonadotropin-releasing hormone (GnRH)-antagonist protocol improves clinical outcomes in women with poor ovarian response (POR) compared with a standard high-dose antagonist regimen.
methodsThis prospective cohort study included 31 women with POR according to the Bologna criteria who underwent two sequential in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) stimulation cycles: a standard-dose r-FSH protocol (300 IU/day), followed by a low-dose r-FSH protocol (150 IU/day) combined with CC (100 mg/day, cycle days 3-7). Each patient served as her own control. The primary outcome was the ongoing pregnancy rate. Secondary outcomes included follicle number, metaphase II (MII) oocytes, embryos, fertilization rate, biochemical and clinical pregnancy, and miscarriage. Statistical analyses included paired t-tests, Wilcoxon signed-rank tests, and Fisher's exact tests.
resultsThe number of follicles ≥ 17 mm and the number of mature oocytes retrieved were comparable between the standard-dose and CC/low-dose protocols (3.00 vs 2.90 follicles, p=0.665; 2.19 vs 2.06 MII oocytes, p = 0.462). Fertilization rates (27/68 (39.7%) vs 35/64 (54.7%), p = 0.116), total embryos (27 (0.87) vs 35 (1.13), p = 0.101), transferred embryos, and biochemical or clinical pregnancy rates did not differ significantly between protocols. No ongoing pregnancies occurred in the standard group, while three (3/31) were achieved after CC/low-dose stimulation (0% vs 9.7%, p = 0.238).
conclusionsIn women with POR, adding CC to a low-dose GnRH-antagonist protocol results in comparable ovarian response and pregnancy outcomes to a standard high-dose regimen, with the potential advantages of lower gonadotropin use and reduced cost. CC-based mild stimulation represents a viable alternative following an unsuccessful high-dose cycle.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.